Abstract

In search of the best anticancer agents, a series of novel fused [1,2,3]triazolo[4',5':3,4] pyrrolo[2,1-f]purine derivatives in one vessel was synthesized using 8-bromo-1,3-dimethyl-7-(prop-2-yn-1-yl)-1H-purine-2,6(3H,7H)-dione and various arylazides. The newly synthesized derivatives were evaluated for their in vitro anti-proliferative activity against four human cancer cell lines (MCF-7, HeLa, A-549 and U-87MG). 3-(3,5-dichlorophenyl)-5,7-dimethyl-7,10-dihydro-[1,2,3]triazolo[4',5':3,4]pyrrolo[2,1-f]purine-6,8(3H,5H)-dione and 5,7-dimethyl-3-(4-nitrophenyl)-3,10-dihydro-[1,2,3]triazolo[4',5':3.4]pyrrolo[2,1-f]purine-6,8 (5H,7H)-dione are showed stronger activity against MCF-7 and A-549 with IC₅₀ values ranging from 11.5 ± 0.64 to 15.3 ± 0.81 μM, which are comparable to the standard drug doxorubicin. Molecular docking studies have also been conducted to complement the experimental results.

中文翻译：

---

新型融合 [1,2,3] 三唑并 [4',5':3,4] 吡咯并 [2,1-f] 嘌呤作为有效抗增殖剂的合成和生物学评价

摘要

在寻找最佳抗癌剂，一系列新的稠合的[1,2,3]三唑并[4' ，5' ：3,4]吡咯并[2,1- ˚F使用8-]在一个容器中的嘌呤衍生物的合成溴-1,3-二甲基-7-(prop-2-yn-1-yl)-1H-purine-2,6(3 H ,7 H )-dione 和各种芳基叠氮化物。评估了新合成的衍生物对四种人类癌细胞系（MCF-7、HeLa、A-549 和 U-87MG）的体外抗增殖活性。3-(3,5-二氯苯基)-5,7-二甲基-7,10-二氢-[1,2,3]三唑并[4',5':3,4]吡咯并[2,1- f ]嘌呤-6,8(3 H ,5 H )-二酮和 5,7-二甲基-3-(4-硝基苯基)-3,10-二氢-[1,2,3]三唑并[4',5':3.4 ]pyrrolo[2,1 - f ]purine-6,8 (5 H ,7H )-二酮对 MCF-7 和 A-549 显示出更强的活性，IC ₅₀值范围为 11.5 ± 0.64 至 15.3 ± 0.81 μM，与标准药物多柔比星相当。还进行了分子对接研究以补充实验结果。